Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,343 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07118436Recruiting
Liquid biopsy during PSMA radiation therapy
This trial studies blood tests (liquid biopsies) in men with metastatic prostate cancer that no longer responds to hormone therapy or chemotherapy and who are receiving a type of radiation therapy called PSMA RLT. The goal is to see if these blood tests can provide useful information about the cancer and treatment response.
AugsburgAges Any age - NCT07125183RecruitingPhase 2
Weekly chemo for advanced leiomyosarcoma in older adults
This trial tests whether weekly doxorubicin is effective and tolerable for people aged 65 and older with advanced or metastatic leiomyosarcoma. It may be a good option if you have not had this type of chemo before.
Aurora, ColoradoAges 65–100 - NCT07116057RecruitingPhase 1
CAR T cell therapy for FRa-positive cancers
This trial tests a new treatment called MOv19-BBz CAR T cells, which are specially designed immune cells that target a protein called FRa found on some cancer cells. It's for people with advanced lung cancer that has spread to the lining of the lung (malignant pleural effusion) and who have already tried at least one standard treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06966141Recruiting
Real-World Study of Sacituzumab Govitecan for Breast Cancer
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT07106762RecruitingPhase 2/Phase 3
Study of new targeted drug vs chemo for bladder cancer
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Gilbert, ArizonaAges 18 years+ - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT07111832RecruitingPhase 3
Study of SHR-A1811 for triple-negative breast cancer
This study tests a new drug called SHR-A1811 for people with triple-negative breast cancer that has spread or come back. It looks at whether the drug can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07112599Recruiting
AI predicts lymph node spread in high-risk prostate cancer
This study uses artificial intelligence to examine MRI and other health data to better predict if high-risk prostate cancer has spread to nearby lymph nodes. Researchers hope this will help guide treatment decisions.
Hefei, AnhuiAges 50 years+ - NCT07114939RecruitingPhase 1
A new pet scan for pancreatic neuroendocrine tumors
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07111507RecruitingPhase 2
Tarlatamab for advanced prostate cancer
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
San Diego, CaliforniaAges 18 years+ - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT07112209Enrolling by invitation
Rezvilutamide plus chemo for prostate cancer
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07110064RecruitingPhase 2
A new combo therapy for advanced pancreatic cancer
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
NanjingAges 18 years+ - NCT04072042RecruitingPhase 2
Test a VEGFR2 drug for sarcoma with lung lesions
This Phase 2 study tests a VEGFR2-targeted medicine in people with advanced or metastatic sarcoma whose cancer cannot be fully removed by surgery. It focuses on participants who have lung (pulmonary) lesions and whose prior standard chemotherapy did not work, to see if the biomarker-driven approach can improve outcomes.
Shanghai, Shanghai MunicipalityAges 8–65 - NCT02971358Recruiting
Surgery for very high-risk or limited-spread prostate cancer
This trial looks at how safe and how well early prostate surgery works for men with newly diagnosed very high-risk prostate cancer or a limited number of metastases (cancer spread). It may help some people live longer and control the cancer, but eligibility is very specific.
ViennaAges 18–75 - NCT07100704RecruitingPhase 2
Nivolumab for recurrent olfactory neuroblastoma
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Kashiwa, ChibaAges 18 years+ - NCT07096128RecruitingPhase 1
PSMA-targeted radioactive injection for advanced prostate cancer
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07096999Recruiting
PET scan to plan treatment for prostate cancer
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
Ann Arbor, MichiganAges 18 years+ - NCT07101744RecruitingPhase 2
Drug combination study for advanced nasopharyngeal cancer
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
GuangdongAges 18–70 - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
Huntsville, AlabamaAges 18 years+ - NCT07102901RecruitingPhase 2
Study of SHR2554 with other therapies for gastric or junction cancer
This trial tests a new drug, SHR2554, combined with other anticancer treatments for advanced stomach or gastroesophageal junction cancer. It aims to see if the combination is safe and effective. You may qualify if you have measurable disease and are generally in good health.
Harbin, HeilongjiangAges 18–75
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,343 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.